文献速递性腺与生殖内分泌

睾酮介导的红细胞生成过程中铁代谢标志物在患有不明原因贫血或缺铁性贫血的老年男性中的变化

Markers of Iron Flux during Testosterone-Mediated Erythropoiesis in Older Men with Unexplained or Iron-Deficiency Anemia.
PubMed 文献 · J Clin Endocrinol Metab · 2020-01-01

该安慰剂对照研究纳入95例≥65岁性腺功能减退(睾酮<275 ng/mL)伴贫血(血红蛋白<12.7 g/dL)的男性,其中不明原因贫血58例、缺铁性贫血37例,随机接受睾酮或安慰剂凝胶治疗1年。结果显示睾酮显著升高不明原因贫血组血红蛋白(校正均差0.58 g/dL,95%CI 0.31-0.85,P<0.001),并抑制铁调素和铁蛋白;缺铁性贫血组血红蛋白变化未达统计学显著(0.38 g/dL,95%CI -0.19-0.95,P=0.19)。

要点

  • 睾酮治疗显著升高不明原因贫血组血红蛋白(校正均差0.58 g/dL,P<0.001),缺铁性贫血组未达统计学显著(P=0.19)。
  • 不明原因贫血组睾酮治疗抑制铁调素(-8.2 ng/mL,P=0.004)和铁蛋白(-19.6 µg/L,P=0.004),缺铁性贫血组无此效应。
  • 不明原因贫血组铁调素下降与血红蛋白升高呈中度相关(相关系数-0.35,P=0.01),缺铁性贫血组无相关(相关系数-0.07,P=0.73)。

核心结论

  • 睾酮替代治疗可刺激不明原因贫血的老年性腺功能减退男性红细胞生成,并伴随铁动员增加,该效应似乎被缺铁减弱。

研究设计与样本

  • 睾酮试验中的贫血子研究,安慰剂对照研究,纳入12个学术医学中心的95例≥65岁性腺功能减退(睾酮<275 ng/mL)伴贫血(血红蛋白<12.7 g/dL)男性,其中不明原因贫血58例、缺铁性贫血37例,干预为睾酮或安慰剂凝胶治疗1年,主要结局指标为治疗前3个月铁代谢标志物。

主要发现

  • 不明原因贫血组睾酮替代显著升高血红蛋白(校正均差0.58 g/dL,95%CI 0.31-0.85,P<0.001)。
  • 缺铁性贫血组睾酮替代有升高血红蛋白趋势(0.38 g/dL,95%CI -0.19-0.95),但反应更多变且未达统计学显著(P=0.19)。
  • 不明原因贫血组睾酮替代抑制铁调素(-8.2 ng/mL,95%CI -13.7至-2.7,P=0.004)和铁蛋白(-19.6 µg/L,95%CI -32.8至-6.3,P=0.004),缺铁性贫血组无此效应。
  • 不明原因贫血组铁调素下降与血红蛋白升高呈中度相关(相关系数-0.35,P=0.01),缺铁性贫血组无相关(相关系数-0.07,P=0.73)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Testosterone treatment of hypogonadal men improves their hemoglobin, but the mechanism is not understood. OBJECTIVE: To investigate possible mechanisms by which testosterone stimulates erythropoiesis in hypogonadal older men with unexplained or iron-deficiency anemia. DESIGN: The Anemia Trial of The Testosterone Trials, a placebo-controlled study in older, hypogonadal men. SETTING: Twelve academic medical centers. PARTICIPANTS: A total of 95 hypogonadal men (testosterone < 275 ng/mL) ≥65 years with anemia (hemoglobin < 12.7 g/dL). They were classified as having unexplained (n = 58) or iron deficiency anemia (n = 37). INTERVENTION: Testosterone or placebo gel for 1 year. MAIN OUTCOME MEASURES: Markers of iron metabolism during the first 3 months of treatment. RESULTS: Testosterone replacement significantly (P < 0.001) increased hemoglobin in the 58 men who had unexplained anemia (adjusted mean difference 0.58 g/dL; 95% confidence interval, 0.31-0.85). Testosterone replacement tended to increase hemoglobin in the 37 men who had iron deficiency (0.38 g/dL; -0.19, 0.95), but the response was more variable and not statistically significant (P = 0.19). In men with unexplained anemia, testosterone replacement suppressed hepcidin (-8.2 ng/mL; -13.7, -2.7; P = 0.004) and ferritin (-19.6 µg/L; -32.8, -6.3; P = 0.004), but in men with iron deficiency, testosterone replacement did not. The decrease in hepcidin was moderately correlated with the increase in hemoglobin in the men with unexplained anemia (correlation coefficient -0.35, P = 0.01) but not in those with iron deficiency anemia (correlation coefficient -0.07, P = 0.73). CONCLUSIONS: Testosterone replacement of older hypogonadal men with unexplained anemia stimulates erythropoiesis associated with increased iron mobilization. This effect appears to be attenuated by iron deficiency.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Artz AS, Stephens-Shields AJ, Bhasin S, et al. Markers of Iron Flux during Testosterone-Mediated Erythropoiesis in Older Men with Unexplained or Iron-Deficiency Anemia. J Clin Endocrinol Metab. 2020. PMID: 32785689. doi:10.1210/clinem/dgaa521

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。